A marker study of therapeutically transduced CD4+ peripheral blood lymphocytes in HIV discordant identical twins

Human Gene Therapy

Volumn 10, Issue 8, 1999, Pages 1401-1421

  Cooper, David ^a,b   Penny, Ronald ^a,c   Symonds, Geoff ^a   Carr, Andrew ^a,c   Gerlach, Wayne ^a   Sun, Lun Quan ^a   Ely, Julie ^a  

^a JOHNSON AND JOHNSON   (United States)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c ST VINCENT S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2; OKT 3;

ARTICLE; CASE REPORT; CLINICAL PROTOCOL; CLINICAL TRIAL; EXPRESSION VECTOR; GENE THERAPY; GENETIC TRANSDUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE SUBPOPULATION; PERIPHERAL LYMPHOCYTE; PHASE 1 CLINICAL TRIAL; TWINS;

HUMAN IMMUNODEFICIENCY VIRUS;

EID: 0033587142     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950018067     Document Type: Article

References (68)

1. Office Recombinant DNA Advisory Commission (1994). ORDA Reports. Hum. Gene Ther. 5, 1295-1310.
2. Agrawal, S., and Tang, J.Y. (1992). GEM 91 - an antisense oligonucleotide phosphorothioate as a therapeutic agent for AIDS. Antisense Res. Dev. 2, 261-266.
3. Amado, R.G., Symonds, G., Jamieson, B.G., Zhao, G., Rosenblatt, J.D., and Zack, J.A. (1998). Effects of megakaryocyte growth and development factor on survival and retroviral transduction of T lymphoid progenitor cells. Hum. Gene Ther. 9, 173-183.
4. Anderson, W.F. (1984). Prospects for human gene therapy. Science 226, 401-409.
5. Anderson, W.F. (1992). Human gene therapy. Science 256, 808-813.
6. Anderson, W.F. (1998). Human gene therapy. Nature 392, Suppl., 25-30.
7. Barre-Sinoussi, F. (1996). HIV as the cause of AIDS. Lancet 348, 31-35.
8. - SCID: Initial trial results after 4 years. Science 270, 475-480.
9. Bridges, S.H., and Sarver, N. (1995). Gene therapy and immune restoration for HIV disease. Lancet 345, 427-432.
10. Carr, A., Samaras, K., Burton, S., Law, M., Freund, J., Chisholm, D.J., and Cooper, D.A. (1988a). A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12, F51-F58.
11. Carr, A., Samaras, K., Chisholm, D.J., and Cooper, D.A. (1988b). Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 351, 1881-1883.
12. Culver, K. (1994). Gene Therapy. A handbook for physicians (Mary Ann Liebert Inc).
13. Duan, L.X., Zhang, H., Oakes, J.W., Bagasra, O., and Pomerantz, R.J. (1994). Molecular and virological effects of intracellular anti-rev single-chain variable fragments on the expression of various human immunodeficiency virus-1 strains. Hum. Gene Ther. 5, 1315-1324.
14. Duan, L.X., Zhu, M.H., Bagasra, O., and Pomerantz, R.J. (1995). Intracellular immunization against HIV-1 infection of human T lymphocytes: Utility of anti-rev single-chain variable fragments. Hum. Gene Ther. 6, 1561-1573.
15. Escaich, S., Kalfoglou, C., Plavec, I., Kaushal, S., Mosca, J.D., and Böhnlein, E. (1995). RevM10-mediated inhibition of HIV-1 replication in chronically infected T cells. Hum. Gene Ther. 6, 625-634.
16. Fauci, A.S. (1993). Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 262, 1011-1018.
17. Finzi, D., and Siliciano, R.F. (1998). Viral dynamics in HIV-1 infection. Cell 93, 665-671.
18. Gilboa, E., and Smith, C. (1994). Gene therapy for infectious diseases: The AIDS model. Trends Genet. 10, 139-144.
19. Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M., and Markowitz, M. (1995). Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373, 123-126.
20. Johnston, M.I., and Hoth, D.F. (1993). Present status and future prospects for HIV therapies. Science 260, 1286-1293.
21. Jolly, D. (1994). Viral vector systems for gene therapy. Cancer Gene Ther. 1, 51-64.
22. Junker, U., Rittner, K., Homann, M., Bevec, D., Bohnlein, E., and Sczakiel, G. (1994). Reduction in replication of the human immunodeficiency virus type 1 in human T cell lines by polymerase III-driven transcription of chimeric tRNA-antisense RNA genes. Antisense Res. Dev. 4, 165-172.
23. + T lymphocytes for clinical application. Gene Ther., in press.
24. Kuritzkes, D.R. (1996). Clinical significance of drug resistance in HIV-1 infection. AIDS 10 Suppl 5, S27-31.
25. Kuwabara, T., Amontov, S.V., Warashina, M., Ohkawa, J., and Taira, K. (1996). Characterization of several kinds of dimer minizyme: simultaneous cleavage at two sites in HIV-1 tat mRNA by dimer minizymes. Nuclei Acids Res. 24, 2302-2310.
26. Leavitt, M.C., Yu, M., Yamada, O., Kraus, G., Looney, D., Poeschla, E., and Wong-Staal, F. (1994). Transfer of an anti-HIV-1 ribozyme gene into primary human lymphocytes. Hum. Gene Ther. 5, 1115-1120.
27. Lee, S.W., Gallardo, H.F., Gilboa, E., and Smith, C. (1994). Inhibition of human immunodeficiency virus type 1 in human T cells by a potent Rev response element decoy consisting of the 13-nucleotide minimal Rev-binding domain. J. Virol. 68, 8254-8264.
28. Levy, J.A. (1993). Pathogenesis of human immunodeficiency virus infection. Microbiol. Rev. 57, 183-289.
29. Lisziewicz, J., Sun, D., Metelev, V., Zamecnik, P., Gallo, R.C., and Agrawal, S. (1993a). Long-term treatment of Human Immunodeficiency Virus-infected cells with antisense oligonucleotide phosphorothioates. Proc. Natl. Acad. Sci. USA 90, 3860-3864.
30. Lisziewicz, J., Sun, D., Smythe, J., Lusso, P., Lori, F., Louie, A., Markham, P., Rossi, J., Reitz, M., and Gallo, R.C. (1993b). Inhibition of human immunodeficiency virus type 1 replication by regulated expression of a polymeric Tat activation response RNA decoy as a strategy for gene therapy in AIDS. Proc. Natl. Acad. Sci. USA 90, 8000-8004.
31. Liu, J.S., Woffendin, C., Yang, Z.Y., and Nadel, G.J. (1994). Regulated expression of a dominant negative form of rev improves resistance to HIV replication in T cells. Gene Ther. 1, 32-37.
32. Lo, K.M., Biasolo, M.A., Dehni, G., Palu, G., and Haseltine, W.A. (1992). Inhibition of replication of HIV-1 by retroviral vectors expressing tat-antisense and anti-tat ribozyme RNA. Virology 190, 176-183.
33. Lowenstein, P., and Symonds, G. (1997). Inhibition of Moloney murine leukaemia virus by a retroviral vector, LNL6, carrying ribozymes targeted to the 5′ non-coding sequence. J. Gen. Virol. 78, 2587-2590.
34. Maciejewski, J.P., Weichold, F.F., Young, N.S., Cara, A., Zella, D., Reitz, M.S., Jr., and Gallo, R.C. (1995). Intracellular expression of antibody fragments directed against HIV reverse transcriptase prevents HIV infection in vitro. Nat. Med. 1, 667-673.
35. Malim, M.H., Freimuth, W.W., Liu, J., Boyle, T.J., Lyerly, H.K., Cullen, B.R., and Nabel, G.J. (1992). Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J. Exp. Med. 176, 1197-1201.
36. Mann, R., Mulligan, R.C., and Baltimore, D. (1983). Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus. Cell 33, 153-159.
37. Miller, A., Miller, D., Garcia, J., and Lynch, C. (1993). Use of retroviral vectors for gene transfer and expression. Methods Enzymol. 217, 581-599.
38. Miller, A.D. (1992). Human gene therapy comes of age. Nature 357, 455-460.
39. Miller, A.D., and Buttimore, C. (1986). Redesign of retrovirus packaging cell lines to avoid recombination leading to helper virus production. Mol. Cell. Biol. 6, 2895-2902.
40. Morgan, R.A., and Anderson, W.F. (1993). Human gene therapy. Annu. Rev. Biochem. 62, 191-217.
41. Mulligan, R.C. (1993). The basic science of gene therapy. Science 260, 926-932.
42. Nabel, G.J., Fox, B.A., Post, L., Thompson, C.B., and Woffendin, C. (1994). A molecular genetic intervention for AIDS - effects of a transdominant negative form of Rev. Hum. Gene Ther. 5, 79-92.
43. Nichols, E.K. (1988). Human gene therapy (National Academy of Sciences, Harvard University Press).
44. Pantaleo, G., Graziosi, C., Demarest, J.F., Butini, L., Montroni, M., Fox, C.H., Orenstein, J.M., Kotler, D.P., and Fauci, A.S. (1993). HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 362, 355-358.
45. Perelson, A.S., Neumann, A.U., Markowitz, M., Leonard, J.M., and Ho, D.D. (1996). HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 271, 1582-1586.
46. Perrin, L., and Telenti, A. (1998). HIV treatment failure: testing for HIV resistance in clinical practice. Science 280, 1871-1873.
47. Ranga, U., Woffendin, C., Verma, S., Xu, L., June, C.H., Bishop, D.K., and Nabel, G.J. (1998). Enhanced T cell engraftment after retroviral delivery of an antiviral gene in HIV-infected individuals. Proc. Natl. Acad. Sci. USA 95, 1201-1206.
48. Ratner, L. (1994). Molecular biology and pathogenesis of HIV infection. Curr. Opin. Infect. Dis. 6, 181-190.
49. Sarver, N., Cantin, E.M., Chang, P.S., Zaia, J.A., Ladne, P.A., Stephens, D.A., and Rossi, J.J. (1990). Ribozymes as potential anti-HIV-1 therapeutic agents. Science 247, 1222-1225.
50. Smythe, J.A., and Symonds, G. (1995). Gene therapeutic agents: the use of ribozymes, antisense, and RNA decoys for HIV-1 infection -review. Inflamm. Res. 44, 11-15.
51. Steffy, K.R., and Wong Staal, F. (1993). Transdominant inhibition of wild-type human immunodeficiency virus type 2 replication by an envelope detection mutant. J. Virol. 67, 1854-1859.
52. Sun, L.Q., Ely, J.A., Gerlach, W., and Symonds, G. (1997). Anti-HIV ribozymes. Mol. Biotechnol. 7, 241-251.
53. Sun, L.Q., Gerlach, W.L., and Symonds, G. (1996). The use of ribozymes to inhibit HIV replication. In Catalytic RNA, (Springer Verlag, Berlin) F. Eckstein and D. Lilley, eds., pp. 329-342.
54. Sun, L.Q., Gerlach, W.L., and Symonds, G. (1998). The design, production and validation of an anti-HIV type 1 ribozyme. In Therapeutic Application of Ribozymes, K.J. Scanlon, ed. (Humana Press Inc, Totowa, NJ), pp. 51-64.
55. Sun, L.Q., Pyati, J., Smythe, J., Wang, L., Macpherson, J., Gerlach, W., and Symonds, G. (1995a). Resistance to human immunodeficiency virus type 1 infection conferred by transduction of human peripheral blood lymphocytes with ribozyme, antisense or polymeric trans-activation response element constructs. Proc. Natl. Acad. Sci. USA 92, 7272-7276.
56. Sun, L.Q., and Symonds, G. (1994). Gene therapy to inhibit HIV replication. Today's Life Sciences, 52-58.
57. Sun, L.Q., Wang, L., Gerlach, W.L., and Symonds, G. (1995b). Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tar RNA. Nucleic Acids Res. 23, 2909-2913.
58. Sun, L.Q., Warrilow, D., Wang, L., Witherington, C., Macpherson, J., and Symonds, G. (1994). Ribozyme-mediated suppression of Moloney murine leukemia virus and human immunodeficiency virus type I replication in permissive cell lines. Proc. Natl. Acad. Sci. USA 91, 9715-9719.
59. Verma, I.M., and Somia, N. (1997). Gene therapy - promises, problems and prospects. Nature 389, 239-242.
60. Walker, R., Blaese, R.M., Carter, C.S., Chang, L., Klein, H., Lane, H.C., Leitman, S.F., Mullen, C.A., and Larson, M. (1993). A study of the safety and survival of the adoptive transfer of genetically marked syngeneic lymphocytes in HIV-Infected identical twins. Hum. Gene Ther. 4, 659-680.
61. + T-cell regeneration HIV-infected adults. Nat. Med. 4, 852-856.
62. Wang, L., Witherington, C., King, A., Gerlach, W.L., Carr, A., Penny, R., Cooper, D., Symonds, G., and Sun, L.Q. (1998). Preclinical characterization of an anti-tat ribozyme for therapeutic application. Hum. Gene Ther. 9, 1283-1291.
63. + lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J. Virol. 65, 5531-5534.
64. Wei, X.P., Ghosh, S.K., Taylor, M.E., Johnson, V.A., Emini, E.A., Deutsch, P., Lifson, J.D., Bonhoeffer, S., Nowak, M.A., Hahn, B.H., Saag, M.S., and Shaw, G.M. (1995). Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373, 117-122.
65. Weiss, R.A. (1993). How does HIV cause AIDS? Science 260, 1273-1279.
66. Woffendin, C., Ranga, U., Yang, Z.-Y., Xu, L., and Nabel, G.J. (1996). Expression of a protective gene prolongs survival of T-cells in human immunodeficiency virus-infected patients. Proc. Natl. Acad. Sci. USA 93, 2889-2894.
67. Yu, M., Poeschla, E., and Wong-Staal, F. (1994). Progress towards gene therapy for HIV infection. Gene Ther. 1, 13-26.
68. Zaia, J.A., Rossi, J.J., Ito, J.I., Castanotto, D., Li, S., Yam, P., Bauer, G., Valdez, P., Rice, C.R., Rothchild, J.C., Li, H., Banh, V.N., Sauter, S., Peters, G., Parker, V., Jolly, D.J., Sniecinski, I., Forman, S.J., and Kohn, D.B. (1998). One year results after autologous stem cell transplantation using retrovirus-transduced peripheral blood progenitor cells in HIV-infected subjects. Blood Suppl, in press.